Discontinuation of Biosimilar Infliximab Associated With Subjective Complaints
Transitioning from an originator agent to its biosimilar has the potential to reduce healthcare costs without compromising outcomes.
Transitioning from an originator agent to its biosimilar has the potential to reduce healthcare costs without compromising outcomes.
The use of tumor necrosis factor inhibitors to modify structural changes in axial spondyloarthritis may prevent progression to spinal disease.
For patients with ankylosing spondylitis, secukinumab may reduce radiographic progression and remain effective in the long-term.
The guideline includes recommendations for treating adult patients with active psoriatic arthritis.
Treatment with TNF inhibitors has led to improvement in physical function and quality of life in patients with ankylosing spondylitis.
Results from phase 3 trials OPAL Broaden (NCT01877668) and OPAL Beyond (NCT01882439) presented at the American College of Rheumatology 2017 in San Diego, California.
Researchers recruited patients with recent onset axial spondyloarthritis and conducted MRI of the spine or MRI of the sacroiliac joints at baseline, 2 years, and 5 years.
Researchers observed a higher prevalence of psychiatric disorders among female patients with psoriatic arthritis.
Real-world data indicate that although most patients with systemic lupus erythematosus or connective tissue diseases have successful pregnancies, more adverse pregnancy outcomes occur.
Investigators sought to determine the long-term safety of adalimumab use in patients with arthritis and other immune-related diseases.